Adaptimmune CEO Adrian Rawcliffe at EUBIO22 (Rachel Kiki for Endpoints News)
Months after reorg, Adaptimmune merges with fellow cell therapy developer
Adaptimmune is merging with TCR² Therapeutics in a bid to create a T cell therapy developer aimed at solid tumors.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
